Skip to main content
Premium Trial:

Request an Annual Quote

Analytik Jena's FY 2012 Revenues Climb 9 Percent

NEW YORK (GenomeWeb News) – German analytic instrument firm Analytik Jena today said that revenues for its Fiscal Year 2012 increased 9 percent year over year.

For the fiscal year ended Sept. 30, Analytik Jena posted €94.0 million ($124.4 million) in revenues, up from €86.3 million a year ago.

Analytical Instrumentation, the company's largest segment, recorded €60.0 million in revenues, up from €53.2 million a year ago, it said in a statement, while Life Science was virtually flat at €28.2 million, compared to €28.3 million a year ago.

The firm's Optics business had sales of €5.8 million, up from €4.8 million in FY 2011.

"We are working intensively on the international positioning of the comparatively young Life Science segment, and have made progress in some important areas," Analytik Jena CEO Klaus Berka said in the company's statement. "For example, double-digit growth in revenue from PCR products and reagents meant that we were able to compensate for the lower revenue from two subsidiaries."

The firm's R&D costs were reduced 8 percent to €7.3million from €7.9 million a year ago, while SG&A spending rose 9 percent to €33.6 million from €30.9 million.

Analytik Jena's profits attributable to shareholders of the parent firm for FY 2012 increased to €3.2 million, or €.59 per share, compared to a loss of €23,000, or €.03 per share, a year ago.

The firm had €21.5 million in cash and cash equivalents as of the Sept. 30.

"The aim of the Analytik Jena Group for the coming year is to further reinforce and expand our position on the global markets," Berka said. "Our objectives are to generate further revenue growth, exceed the highs recorded in 2011/2012, and ensure qualitative earnings growth."

Revenue growth and profits will be driven by the company's Asian business, which in FY 2012 grew 31 percent year over year, as well as new product launches, it said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more